Zika Virus Clinical Trial
Official title:
Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers
Verified date | August 2022 |
Source | Themis Bioscience GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Double blinded, randomized, placebo-controlled, dose finding, multi-center, phase 1 trial in 48 healthy volunteer subjects. After completion of screening procedures, the subjects are randomized to one of four treatment groups (different dosage strengths and placebo) All subjects will receive study treatment at day 0 and will return on day 28. Subjects randomized to treatment groups with two vaccinations will receive a second treatment at day 28. Subjects will return on day 56 for the final visit.
Status | Completed |
Enrollment | 48 |
Est. completion date | April 17, 2018 |
Est. primary completion date | January 4, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - healthy volunteers aged 18 to 55 - subjects of child bearing potential must perform reliable method of contraception Exclusion Criteria: - immune deficiency, history of HIV, HBV, HCV - drug addiction - vaccination within 4 weeks prior to study or planned vaccination during study - prior receipt of any Zika vaccine - recent infection 1 week prior to screening - relevant medical history interfering with aim of study - neoplastic disease, hematological malignancy - history of autoimmune disease - psychological condition that affects ability to participate in the study - history of severe adverse reactions to vaccine administration - history of anaphylaxis - allergic reactions, abnormal lab values, or concomitant medication per decision of the investigator - use of immunosuppressive drugs within 30 days before screening or planned use during study - receipt of blood products within 120 days before screening or planned use during study - pregnancy, unreliable contraception method - decision of the investigator - regular blood plasma donor |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University of Vienna, Center for Pathophysiology, Infectiology and Immunology | Vienna | |
Austria | Medical University of Vienna, Department of Clinical Pharmacology | Vienna |
Lead Sponsor | Collaborator |
---|---|
Themis Bioscience GmbH |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Immunogenicity: Functional anti-Zika antibodies as measured by PRNT | Functional anti-Zika antibodies as measured by PRNT. | 56 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04182685 -
Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua
|
||
Enrolling by invitation |
NCT04398901 -
Neurodevelopmental Outcomes in ZIKV-Exposed Children
|
||
Completed |
NCT03188731 -
ZIKAlliance Pregnant Women Cohort
|
||
Completed |
NCT03110770 -
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
|
Phase 2 | |
Active, not recruiting |
NCT04917861 -
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
|
Phase 2 | |
Completed |
NCT02794181 -
Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
|
||
Recruiting |
NCT01099852 -
Cohort of Patients Infected by an Arbovirus
|
||
Completed |
NCT03611946 -
Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults
|
Phase 1 | |
Completed |
NCT04064905 -
Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
|
Phase 1 | |
Completed |
NCT03106714 -
Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil
|
||
Completed |
NCT02979938 -
Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection
|
||
Recruiting |
NCT03227601 -
Effect of a Posture Adapter for 12 to 24-month Children With Zyka Virus Syndrome
|
N/A | |
Completed |
NCT03393286 -
ZIKAlliance Children Cohort (ZIKAllianceCH)
|
||
Completed |
NCT03425149 -
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
|
Phase 1 | |
Recruiting |
NCT05123222 -
Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
|
Phase 1 | |
Completed |
NCT02733796 -
Persistence of Zika Virus in Semen After Acute Infection
|
||
Completed |
NCT03014089 -
Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT03263195 -
Prospective Cohort Study of HIV and Zika in Infants and Pregnancy
|
||
Withdrawn |
NCT03204409 -
ZIKAlliance Natural History Study
|